Stefan Ückert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1038023/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra. Research and Reports in Urology, 2021, Volume 13, 139-145.	0.6	1
2	Reâ€evaluation of the immunohistochemical distribution of isoforms of nitric oxide synthase in the human prostate: A light and electron microscopical study. Andrologia, 2021, 53, e14098.	1.0	1
3	An advanced method for the immunohistochemical detection of nitric oxide synthase (NOS) in the female genital tract. Analytical Biochemistry, 2021, 631, 114264.	1.1	0
4	Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. World Journal of Urology, 2020, 38, 1423-1435.	1.2	15
5	The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. Journal of Clinical Medicine, 2020, 9, 2987.	1.0	11
6	Arginase enzymes in the human prostate: A molecular biological and immunohistochemical approach. Andrologia, 2019, 51, e13349.	1.0	1
7	Development and validation of GC–MS methods for the comprehensive analysis of amino acids in plasma and urine and applications to the HELLP syndrome and pediatric kidney transplantation: evidence of altered methylation, transamidination, and arginase activity. Amino Acids, 2019, 51, 529-547.	1.2	44
8	Course of transforming growth factor ß1 in the systemic and cavernous blood of healthy males through different penile conditions. Andrologia, 2019, 51, e13150.	1.0	1
9	Endopeptidase inhibition attenuates the contraction induced by big endothelinâ€1 of isolated human penile erectile tissue. Andrologia, 2018, 50, e13008.	1.0	1
10	S-Nitroso-N-acetyl-L-cysteine ethyl ester (SNACET) and N-acetyl-L-cysteine ethyl ester (NACET)–Cysteine-based drug candidates with unique pharmacological profiles for oral use as NO, H2S and GSH suppliers and as antioxidants: Results and overview. Journal of Pharmaceutical Analysis, 2018, 8, 1-9.	2.4	24
11	Results, meta-analysis and a first evaluation of UNOxR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings. Amino Acids, 2018, 50, 799-821.	1.2	23
12	Expression and distribution of key proteins of the endocannabinoid system in the human seminal vesicles. Andrologia, 2018, 50, e12875.	1.0	6
13	Is β-endorphin significant in the control of the male sexual response?. Andrologia, 2018, 50, e13049.	1.0	1
14	Protein kinase enzymes in the human vagina—relation to key mediators of the cyclic AMP and cyclic GMP pathways. International Journal of Impotence Research, 2017, 29, 127-131.	1.0	0
15	Expression and distribution of the transient receptor potential cationic channel A1 (TRPA1) in the human clitoris—comparison to male penile erectile tissue. International Journal of Impotence Research, 2017, 29, 179-183.	1.0	5
16	Effects of endopeptidase inhibition on the relaxation response of isolated human penile erectile tissue to vasoactive peptides. Andrologia, 2016, 48, 1214-1219.	1.0	1
17	Expression and Distribution of Phosphodiesterase Isoenzymes in the Human Male Urethra. Urology, 2015, 85, 964.e1-964.e6.	0.5	7
18	Expression and distribution of the transient receptor potential cationic channel ankyrin 1 (TRPA1) in the human vagina. International Journal of Impotence Research, 2015, 27, 16-19.	1.0	10

#	Article	IF	CITATIONS
19	Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opinion on Investigational Drugs, 2014, 23, 1477-1483.	1.9	26
20	Phosphodiesterase isoenzymes in the human urethra: A molecular biology and functional study. European Journal of Pharmacology, 2014, 741, 330-335.	1.7	6
21	Phosphodiesterase type 1, calcitonin gene-related peptide and vasoactive intestinal polypeptide are involved in the control of human vaginal arterial vessels. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 283-286.	0.5	5
22	Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate. World Journal of Urology, 2013, 31, 609-614.	1.2	9
23	Phosphodiesterase inhibitors in clinical urology. Expert Review of Clinical Pharmacology, 2013, 6, 323-332.	1.3	23
24	Pharmacologic Characterization of Human Male Urethral Smooth Muscle: An InÂVitro Approach. Urology, 2013, 82, 1451.e13-1451.e19.	0.5	6
25	The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia. European Urology, 2013, 63, 506-516.	0.9	128
26	The role of phosphodiesterases in bladder pathophysiology. Nature Reviews Urology, 2013, 10, 414-424.	1.9	28
27	Effects of Endopeptidase Inhibition on the Contraction–Relaxation Response of Isolated Human Vaginal Tissue. Journal of Sexual Medicine, 2013, 10, 951-959.	0.3	4
28	The recent phosphodiesterase type 5 inhibitors. Human Andrology, 2012, 2, 57-64.	0.2	0
29	Arginase enzymes in the human prostate: expression of arginase isoenzymes and effects of arginase inhibitors on isolated human prostate tissue. BJU International, 2012, 110, E1196-201.	1.3	3
30	Evaluating the Significance of Cyclic Adenosine Monophosphate-mediated Signaling in Human Prostate: A Functional and Biochemical Study. Urology, 2012, 80, 952.e9-952.e14.	0.5	4
31	Rho Kinase (ROK)â€Related Proteins in Human Cavernous Arteries: An Immunohistochemical and Functional Approach. Journal of Sexual Medicine, 2012, 9, 1337-1343.	0.3	9
32	Systemic and cavernous plasma levels of neuropeptide Y during sexual arousal in healthy males. Andrologia, 2012, 44, 307-311.	1.0	2
33	Is there a significance of histamine in the control of the human male sexual response?. Andrologia, 2012, 44, 538-542.	1.0	6
34	Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms by Phosphodiesterase Inhibitors. Handbook of Experimental Pharmacology, 2011, , 307-322.	0.9	10
35	Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. British Journal of Clinical Pharmacology, 2011, 72, 197-204.	1.1	52
36	Endogenous Vasoactive Peptides and the Human Vagina—A Molecular Biology and Functional Study. Journal of Sexual Medicine, 2011, 8, 35-43.	0.3	10

#	Article	IF	CITATIONS
37	Rho Kinaseâ€related Proteins in Human Vaginal Arteries: An Immunohistochemical and Functional Study. Journal of Sexual Medicine, 2011, 8, 2739-2745.	0.3	3
38	Expression and Distribution of Phosphodiesterase Isoenzymes in the Human Seminal Vesicles. Journal of Sexual Medicine, 2011, 8, 3058-3065.	0.3	10
39	Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5). International Journal of Impotence Research, 2011, 23, 206-212.	1.0	8
40	Cyclic Nucleotide Metabolism Including Nitric Oxide and Phosphodiesterase-Related Targets in the Lower Urinary Tract. Handbook of Experimental Pharmacology, 2011, , 527-542.	0.9	20
41	Expression and Distribution of Cyclic AMP- and Cyclic GMP-Binding Protein Kinases in the Human Vagina— An Immunohistochemical Study. Journal of Sexual Medicine, 2010, 7, 888-895.	0.3	5
42	Anatomy, Physiology, and Pathophysiology of Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 445-475.	0.3	314
43	Expression of Cyclic AMP-dependent Protein Kinase Isoforms in Human Cavernous Arteries: Functional Significance and Relation to Phosphodiesterase Type 4. Journal of Sexual Medicine, 2010, 7, 2104-2111.	0.3	5
44	1405 EVALUATING THE SIGNIFICANCE OF THE CYCLIC AMP-MEDIATED SIGNALLING IN THE CONTROL OF SMOOTH MUSCLE OF THE HUMAN PROSTATE – A FUNCTIONAL AND BIOCHEMICAL STUDY. Journal of Urology, 2010, 183, .	0.2	1
45	Potential Mechanism of Action of Human Growth Hormone on Isolated Human Penile Erectile Tissue. Urology, 2010, 75, 968-973.	0.5	13
46	Characterization of the Effects of Various Drugs Likely to Affect Smooth Muscle Tension on Isolated Human Seminal Vesicle Tissue. Urology, 2010, 75, 974-978.	0.5	16
47	Expression of cAMP-dependent Protein Kinase Isoforms in the Human Prostate: Functional Significance and Relation to PDE4. Urology, 2010, 76, 515.e8-515.e14.	0.5	14
48	Exposure of Human Seminal Vesicle Tissue to Phosphodiesterase (PDE) Inhibitors Antagonizes the Contraction Induced by Norepinephrine and Increases Production of Cyclic Nucleotides. Urology, 2010, 76, 1518.e1-1518.e6.	0.5	16
49	C-kit-positive multipolar cells in human penile erectile tissue: expression of connexin 43 and relation to trabecular smooth muscle cells. Georgian Medical News, 2010, , 13-9.	0.0	2
50	Effects of Phosphodiesterase Inhibitors on the Contractile Responses of Isolated Human Seminal Vesicle Tissue to Adrenergic Stimulation. Journal of Sexual Medicine, 2009, 6, 408-414.	0.3	39
51	Evaluating the Role of the Serotoninergic System in the Control of Human Seminal Vesicle Smooth Muscle—An in Vitro Approach. Journal of Sexual Medicine, 2009, 6, 2672-2679.	0.3	9
52	Effects of arginase inhibitors on the contractile and relaxant responses of isolated human penile erectile tissue. World Journal of Urology, 2009, 27, 805-810.	1.2	9
53	Effects of Phosphodiesterase Inhibitors on Contraction Induced by Endothelin-1 of Isolated Human Prostatic Tissue. Urology, 2009, 73, 1397-1401.	0.5	25
54	IS THERE A ROLE OF THE PHOSPHODIESTERASE TYPE 5 (PDE5) IN THE CONTROL OF HUMAN DETRUSOR SMOOTH MUSCLE? A FUNCTIONAL AND MOLECULAR BIOLOGY STUDY. Journal of Urology, 2009, 181, 152-152.	0.2	6

#	Article	IF	CITATIONS
55	Nonâ€genomic effects of androgens on isolated human vascular and nonvascular penile erectile tissue. BJU International, 2008, 101, 71-75.	1.3	21
56	The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World Journal of Urology, 2008, 26, 603-609.	1.2	87
57	Expression and Distribution of Cyclic GMP-Dependent Protein Kinase-1 Isoforms in Human Penile Erectile Tissue. Journal of Sexual Medicine, 2008, 5, 536-543.	0.3	16
58	Effects of Phosphodiesterase Inhibitors on Tension Induced by Norepinephrine and Accumulation of Cyclic Nucleotides in Isolated Human Prostatic Tissue. Urology, 2008, 71, 526-530.	0.5	73
59	EXPRESSION OF PHOSPHODIESTERASE (PDE) ISOENZYMES IN THE HUMAN SEMINAL VESICLE (SV) AND EFFECTS OF PDE INHIBITORS ON THE CONTRACTILE RESPONSES OF ISOLATED HUMAN SEMINAL VESICLE SMOOTH MUSCLE. Journal of Urology, 2008, 179, 235-235.	0.2	1
60	The future of the oral pharmacotherapy of male erectile dysfunction: things to come. Expert Opinion on Emerging Drugs, 2007, 12, 219-228.	1.0	23
61	Functional Responses of Isolated Human Seminal Vesicle Tissue to Selective Phosphodiesterase Inhibitors. Urology, 2007, 70, 185-189.	0.5	29
62	45 CONTRACTION-RELAXATION STUDIES ON ISOLATED HUMAN PROSTATE TISSUE: THE ROLE OF ENDOTHELIN 1, PHOSPHODIESTERASE INHIBITORS, AND CYCLIC NUCLEOTIDES. European Urology Supplements, 2007, 6, 34.	0.1	3
63	Immunohistochemical distribution of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human vagina: A potential forensic value?. Journal of Clinical Forensic and Legal Medicine, 2007, 14, 270-274.	0.5	7
64	Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourology and Urodynamics, 2007, 26, 928-933.	0.8	71
65	Immunohistochemical Distribution of Cyclic GMP-Dependent Protein Kinase-1 in Human Prostate Tissue. European Urology, 2007, 52, 495-502.	0.9	37
66	ORIGINAL RESEARCH—BASIC SCIENCE: Immunohistochemical Description of Cyclic Nucleotide Phosphodiesterase (PDE) Isoenzymes in the Human Labia Minora. Journal of Sexual Medicine, 2007, 4, 602-608.	0.3	13
67	Expression of Messenger Ribonucleic Acid Encoding for Phosphodiesterase Isoenzymes in Human Female Genital Tissues. Journal of Sexual Medicine, 2007, 4, 1604-1609.	0.3	27
68	In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urological Research, 2007, 35, 49-54.	1.5	61
69	Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: Immunohistochemical and molecular biology study. Urology, 2006, 67, 1111-1116.	0.5	32
70	In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology, 2006, 67, 1292-1297.	0.5	23
71	Potential future options in the pharmacotherapy of female sexual dysfunction. World Journal of Urology, 2006, 24, 630-638.	1.2	10
72	Immunohistochemical Distribution of cAMP- and cGMP-Phosphodiesterase (PDE) Isoenzymes in the Human Prostate. European Urology, 2006, 49, 740-745.	0.9	116

#	Article	IF	CITATIONS
73	Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and Future. European Urology, 2006, 50, 1194-1207.	0.9	90
74	Sexualstörungen — Sexuelle Funktionsstörungen. , 2006, , 763-806.		9
75	In vitro functional responses of isolated human vaginal tissue to selective phosphodiesterase inhibitors. World Journal of Urology, 2005, 23, 398-404.	1.2	37
76	Phosphodiesterase inhibitors in female sexual dysfunction. World Journal of Urology, 2005, 23, 393-397.	1.2	37
77	Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract. World Journal of Urology, 2005, 23, 368-373.	1.2	9
78	Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries—immunohistochemical distribution and functional significance. World Journal of Urology, 2005, 23, 405-410.	1.2	31
79	1072: Mechanisms of Action of Human Growth Hormone(GH) on Isolated Human Penile Erectile Tissue. Journal of Urology, 2005, 173, 291-291.	0.2	3
80	Cyclic adenosine monophosphate and cyclic guanosine monophosphate-phosphodiesterase isoenzymes in human vagina: Relation to nitric oxide synthase isoforms and vasoactive intestinal polypeptide-containing nerves. Urology, 2005, 65, 604-610.	0.5	31
81	Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part I). The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2005, 2, 87-94.	0.3	4
82	Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part II). The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2005, 2, 325-332.	0.3	1
83	Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World Journal of Urology, 2004, 22, 261-266.	1.2	53
84	Is serotonin significant for the control of penile flaccidity and detumescence in the human male?. Urological Research, 2003, 31, 55-60.	1.5	16
85	Systemic and cavernous plasma levels of vasopressin in healthy males during different functional conditions of the penis. Urological Research, 2003, 31, 66-69.	1.5	5
86	Immunocytochemical distribution of nitric oxide synthase in the human seminal vesicle: a light and electron microscopical study. Urological Research, 2003, 31, 262-266.	1.5	23
87	Is there an inhibitory role of cortisol in the mechanism of male sexual arousal and penile erection?. Urological Research, 2003, 31, 402-406.	1.5	29
88	Oxytocin plasma levels in the systemic and cavernous blood of healthy males during different penile conditions. World Journal of Urology, 2003, 20, 323-326.	1.2	37
89	Expression of Guanylyl Cyclase B in the Human Corpus Cavernosum Penis and the Possible Involvement of its Ligand C-type Natriuretic Polypeptide in the Induction of Penile Erection. Journal of Urology, 2003, 169, 1918-1922.	0.2	29
90	Current and future trends in the oral pharmacotherapy of male erectile dysfunction. Expert Opinion on Investigational Drugs, 2003, 12, 1521-1533.	1.9	10

#	Article	IF	CITATIONS
91	Growth hormone, somatomedins and men's health. Aging Male, 2002, 5, 258-262.	0.9	6
92	Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction. Urology, 2002, 59, 281-286.	0.5	29
93	Serum levels of human growth hormone during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology, 2002, 59, 609-614.	0.5	28
94	Effects of various nitric oxide donating agents on the contractility and cyclic nucleotide turnover of human seminal vesicles in vitro. Urology, 2002, 59, 958-962.	0.5	31
95	In Vitro Effects of a Novel Class of Nitric Oxide (NO) Donating Compounds on Isolated Human Erectile Tissue. European Urology, 2002, 42, 523-528.	0.9	41
96	Systemic and cavernous plasma levels of vasoactive intestinal polypeptide during sexual arousal in healthy males. World Journal of Urology, 2002, 20, 59-63.	1.2	23
97	Possible role of bioactive peptides in the regulation of human detrusor smooth muscle – functional effects in vitro and immunohistochemical presence. World Journal of Urology, 2002, 20, 244-249.	1.2	26
98	Growth hormone, somatomedins and men's health. Aging Male, 2002, 5, 258-262.	0.9	1
99	Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology, 2001, 57, 193-198.	0.5	85
100	CHARACTERIZATION AND FUNCTIONAL RELEVANCE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOENZYMES OF THE HUMAN PROSTATE. Journal of Urology, 2001, 166, 2484-2490.	0.2	178
101	EXPRESSION OF DIFFERENT PHOSPHODIESTERASE GENES IN HUMAN CAVERNOUS SMOOTH MUSCLE. Journal of Urology, 2001, 165, 280-283.	0.2	77
102	Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World Journal of Urology, 2001, 19, 14-22.	1.2	72
103	Immunocytochemical distribution of nitric oxide synthase in the human corpus cavernosum: an electron microscopical study using the tyramide signal amplification technique. Urological Research, 2001, 29, 168-172.	1.5	25
104	Plasma levels of cyclic guanosine-3′,5′-monophosphate in the cavernous and systemic blood of healthy males during different functional conditions of the penis. Urological Research, 2001, 29, 366-370.	1.5	2
105	Systemic and cavernous plasma levels of endothelin (1-21) during different penile conditions in healthy males and patients with erectile dysfunction. World Journal of Urology, 2001, 19, 267-271.	1.2	23
106	Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: From bench to bedside. World Journal of Urology, 2001, 19, 344-350.	1.2	108
107	Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. Journal of Urology, 2001, 166, 2484-90.	0.2	61
108	Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways. Urological Research, 2000, 28, 110-115.	1.5	40

#	Article	IF	CITATIONS
109	Systemic and cavernous plasma levels of endothelin 1 in healthy males during different functional conditions of the penis. World Journal of Urology, 2000, 18, 227-231.	1.2	11
110	Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World Journal of Urology, 2000, 18, 439-443.	1.2	50
111	Gene Expression of the Phosphodiesterases 3A and 5A in Human Corpus cavernosum Penis. European Urology, 2000, 38, 108-114.	0.9	31
112	Responses of Isolated Normal Human Detrusor Muscle to Various Spasmolytic Drugs Commonly Used in the Treatment of the Overactive Bladder. Arzneimittelforschung, 2000, 50, 456-460.	0.5	18
113	Cavernous and systemic testosterone levels in different phases of human penile erection. Urology, 2000, 56, 125-129.	0.5	31
114	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology, 2000, 55, 146-150.	0.5	130
115	PLASMA LEVELS OF CAVERNOUS AND SYSTEMIC NOREPINEPHRINE AND EPINEPHRINE IN MEN DURING DIFFERENT PHASES OF PENILE ERECTION. Journal of Urology, 2000, 164, 573-577.	0.2	23
116	POSSIBLE ROLE OF HUMAN GROWTH HORMONE IN PENILE ERECTION. Journal of Urology, 2000, 164, 2138-2142.	0.2	29
117	Plasma levels of cavernous and systemic norepinephrine and epinephrine in men during different phases of penile erection. Journal of Urology, 2000, 164, 573-7.	0.2	8
118	Possible role of human growth hormone in penile erection. Journal of Urology, 2000, 164, 2138-42.	0.2	6
119	FURTHER EVIDENCE FOR A FUNCTIONAL ROLE OF cAMP IN THE REGULATION OF HUMAN CAVERNOUS SMOOTH MUSCLE TONE IN VITRO. Journal of Urology, 1999, , 221.	0.2	1
120	Cyclic Nucleotide Phosphodiesterase (PDE) Isoenzymes in the Human Detrusor Smooth Muscle: II. Effect of Various PDE Inhibitors on Smooth Muscle Tone and Cyclic Nucleotide Levels In Vitro. Journal of Urology, 1998, 159, 2263-2263.	0.2	0
121	Cyclic Nucleotide Phosphodiesterase (PDE) Isoenzymes in the Human Detrusor Smooth Muscle: I. Identification and Characterization. Journal of Urology, 1998, 159, 2262-2263.	0.2	0
122	THE EFFECT OF THE SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORS ON HUMAN AND RABBIT CAVERNOUS TISSUE IN VITRO AND IN VIVO. Journal of Urology, 1998, 159, 1390-1393.	0.2	107
123	THE EFFECT OF THE SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORS ON HUMAN AND RABBIT CAVERNOUS TISSUE IN VITRO AND IN VIVO. Journal of Urology, 1998, , 1390-1393.	0.2	3
124	The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. Journal of Urology, 1998, 159, 1390-3.	0.2	19
125	Comparison of the effects of various spasmolytic drugs on isolated human and porcine detrusor smooth muscle. Arzneimittelforschung, 1998, 48, 836-9.	0.5	7
126	Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro. , 1996, 15, 59-70.		31

#	Article	IF	CITATIONS
127	A possible role for nitric oxide in the regulation of human ureteral smooth muscle tone in vitro. Urological Research, 1996, 24, 333-337.	1.5	35
128	Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. Urological Research, 1996, 24, 123-128.	1.5	81
129	Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. Urological Research, 1996, 24, 129-134.	1.5	73
130	Phosphodiesterase Isoenzymes in Human Ureteral Smooth Muscle: Identification, Characterization, and Functional Effects of Various Phosphodiesterase Inhibitors in vitro. Urologia Internationalis, 1995, 55, 183-189.	0.6	32
131	Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: Characterization and functional effects of various phosphodiesterase inhibitors in vitro. Urology, 1995, 45, 893-901.	0.5	29